• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.

作者信息

Navaneethan Udayakumar, Edminister Timothy, Zhu Xiang, Kommaraju Kiran, Glover Sarah

机构信息

*IBD Center, Center for Interventional Endoscopy, Florida Hospital, Orlando, Florida †Department of Gastroenterology, University of Florida, Gainesville, Florida.

出版信息

Inflamm Bowel Dis. 2017 Apr;23(4):E17. doi: 10.1097/MIB.0000000000001071.

DOI:10.1097/MIB.0000000000001071
PMID:28296827
Abstract
摘要

相似文献

1
Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.维多珠单抗在老年炎症性肠病患者中安全有效。
Inflamm Bowel Dis. 2017 Apr;23(4):E17. doi: 10.1097/MIB.0000000000001071.
2
Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.维多珠单抗在肝移植术后中重度炎症性肠病中安全有效。
Liver Transpl. 2017 Jul;23(7):968-971. doi: 10.1002/lt.24757.
3
Efficacy of Vedolizumab for Inflammatory Bowel Disease in the Setting of DiGeorge Syndrome.维多珠单抗在迪格奥尔格综合征背景下治疗炎症性肠病的疗效。
J Pediatr Gastroenterol Nutr. 2019 May;68(5):e88. doi: 10.1097/MPG.0000000000002322.
4
Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?通过维多珠单抗阻断α4β7整合素：必要但不充分？
J Crohns Colitis. 2017 Aug 1;11(8):903-904. doi: 10.1093/ecco-jcc/jjx033.
5
Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.患有炎症性肠病的哺乳期母亲母乳中的维多珠单抗浓度。
Gastroenterology. 2018 Feb;154(3):752-754.e1. doi: 10.1053/j.gastro.2017.08.067. Epub 2017 Oct 5.
6
Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease.致编辑的信：接受维多珠单抗治疗肠道疾病的患者出现新发/复发性炎性关节痛/脊柱关节炎
Clin Rheumatol. 2019 Feb;38(2):609-610. doi: 10.1007/s10067-018-4357-y. Epub 2018 Nov 5.
7
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.维得利珠单抗治疗对炎症性肠病肠外表现的影响。
Dig Dis Sci. 2018 Apr;63(4):825-833. doi: 10.1007/s10620-018-4971-1. Epub 2018 Feb 26.
8
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.维得利珠单抗诱导治疗炎症性肠病患者的有效性和安全性。
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2. doi: 10.1016/j.cgh.2016.02.016. Epub 2016 Feb 22.
9
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study.一项关于 vedolizumab 在炎症性肠病成年患者中的有效性和安全性的真实世界、长期经验：Cross Pennine 研究。
Dig Liver Dis. 2018 Dec;50(12):1299-1304. doi: 10.1016/j.dld.2018.07.007. Epub 2018 Jul 18.
10
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.设计针对炎症性肠病的生物选择性——维多珠单抗的作用
Drug Des Devel Ther. 2014 Dec 17;9:147-54. doi: 10.2147/DDDT.S50348. eCollection 2015.

引用本文的文献

1
Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.维多珠单抗皮下制剂用于炎症性肠病患者的维持治疗：一项系统评价和荟萃分析。
Therap Adv Gastroenterol. 2023 Apr 27;16:17562848231166227. doi: 10.1177/17562848231166227. eCollection 2023.
2
Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease.维多珠单抗在老年炎症性肠病退伍军人患者中是安全的。
Crohns Colitis 360. 2021 Jun 16;3(3):otab025. doi: 10.1093/crocol/otab025. eCollection 2021 Jul.
3
Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management.
炎症性肠病患者的癌症风险及患者管理要点
Cancers (Basel). 2023 Jan 31;15(3):871. doi: 10.3390/cancers15030871.
4
How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease.如何为初治的炎症性肠病患者选择生物治疗方法。
J Clin Med. 2022 Feb 4;11(3):829. doi: 10.3390/jcm11030829.
5
Iatrogenic Kaposi's sarcoma unmasked by Vedolizumab in a patient with ulcerative colitis and well-controlled human immunodeficiency virus: A case report.维多珠单抗暴露的医源性卡波西肉瘤：1例溃疡性结肠炎合并人类免疫缺陷病毒控制良好患者的病例报告
Int J Crit Illn Inj Sci. 2021 Jul-Sep;11(3):177-180. doi: 10.4103/IJCIIS.IJCIIS_92_20. Epub 2021 Sep 25.
6
Clinical characteristics of ulcerative colitis in elderly patients.老年溃疡性结肠炎的临床特征
JGH Open. 2021 Jul 12;5(8):849-854. doi: 10.1002/jgh3.12612. eCollection 2021 Aug.
7
Vedolizumab in Inflammatory Bowel Disease: West versus East.维多珠单抗治疗炎症性肠病：西方与东方的比较
Inflamm Intest Dis. 2021 Feb;6(1):1-17. doi: 10.1159/000512805. Epub 2021 Jan 27.
8
Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.影响 vedolizumab 治疗效果的因素：真实世界数据中的客观疗效评估。
United European Gastroenterol J. 2021 Apr;9(3):398-406. doi: 10.1177/2050640620965106. Epub 2021 Feb 26.
9
How to manage IBD in the 'elderly'.如何管理老年患者的炎症性肠病
Frontline Gastroenterol. 2019 Nov 15;11(6):468-477. doi: 10.1136/flgastro-2019-101218. eCollection 2020 Oct.
10
Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study.维多珠单抗治疗老年炎症性肠病患者的疗效和安全性：一项配对病例对照研究。
Gastroenterol Rep (Oxf). 2019 Sep 17;8(4):306-311. doi: 10.1093/gastro/goz041. eCollection 2020 Aug.